How Echo IQ’s New Deal Could Transform US Heart Disease Detection

Echo IQ’s Strategic US Expansion

Echo IQ Limited, an Australian AI and medical technology company, has taken a significant step forward in its US commercialisation strategy by entering into a reseller agreement with SARC MedIQ, a prominent US-based provider of imaging workflow solutions. This partnership opens immediate doors to over 300 healthcare facilities and clinics, serving more than 1,500 physicians, including a substantial number of cardiologists.

The agreement positions SARC MedIQ as a reseller of Echo IQ’s EchoSolv AS, an AI-driven early detection tool for aortic stenosis, a serious heart valve condition. By leveraging SARC MedIQ’s established network and dedicated sales force, Echo IQ aims to accelerate the adoption of its technology across a broad spectrum of hospitals and cardiology practices in the United States.

Financial and Operational Implications

Under the terms of the agreement, Echo IQ will initially receive fees on a per scan basis from hospitals and clinics within SARC MedIQ’s network. This revenue model is designed to evolve; once Echo IQ secures Category III and Category I CPT codes, key reimbursement classifications in the US healthcare system, the per scan fees will be renegotiated to higher rates, aligning with previous guidance provided to investors.

Echo IQ is actively training SARC MedIQ’s sales team to ensure a smooth integration and effective promotion of EchoSolv AS. This collaboration is expected to reduce Echo IQ’s sales and distribution costs significantly, enabling faster market penetration and scaling across the US healthcare sector. The partnership also offers the potential for a more predictable and recurring revenue stream in the near term.

Building on Previous US Partnerships

This reseller agreement complements Echo IQ’s earlier collaborations with ScImage and MedAxiom, which facilitated the deployment of EchoSolv AS in 36 affiliated hospitals and cardiology practices. Together, these partnerships create a growing distribution footprint, reinforcing Echo IQ’s position in the competitive US cardiology diagnostics market.

Echo IQ’s President in the USA, Don Fowler, highlighted the strategic importance of the deal, emphasizing the opportunity for third-party sales to deliver consistent revenue on a lower cost base. Meanwhile, SARC MedIQ’s CEO, Asaad Hakeem, underscored the alignment of EchoSolv AS with their mission to provide physicians with smarter, faster tools that improve patient outcomes.

Looking Ahead

As Echo IQ and SARC MedIQ move towards integration and expansion phases, the healthcare sector will be watching closely to see how quickly EchoSolv AS gains traction and reimbursement approvals. The success of this partnership could mark a turning point in early aortic stenosis detection and treatment across the US.